Abstract
Children require specific formulations of drugs to avoid risks of overdosing and inefficacy. And, with this in mind, earlier this year the Bill & Melinda Gates Foundation gave nearly $10 million to the World Health Organization (WHO) to work with UNICEF to improve medicines for youngsters. Researchers have estimated that 50–90% of medicines for children have not been tested properly—a serious problem, given that roughly a third of the worldwide population is under age 18. The problem is a crucial one, according to Agnès Saint Raymond, head of the Scientific Advice, Paediatrics and Orphan Drugs sector, which handles applications to study medicines in children for the European Medicines Agency (EMEA). Saint Raymond has long advocated for children's health and worked with members of the European Parliament to draft and pass new legislation in 2006 to promote drug development in this area. She spoke with Genevive Bjorn about the future of medicines designed for youngsters.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bjorn, G. Straight talk with ... Agnès Saint Raymond. Nat Med 15, 354–355 (2009). https://doi.org/10.1038/nm0409-354
Issue Date:
DOI: https://doi.org/10.1038/nm0409-354